Advanced Melanoma Clinical Trials

32 recruitingLast updated: June 17, 2026

There are 32 actively recruiting advanced melanoma clinical trials across 33 countries. Studies span Phase 1, Phase 2, Phase 3, Early Phase 1, Not Applicable, Phase 4. Top locations include Pittsburgh, Pennsylvania, United States, Jacksonville, Florida, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Advanced Melanoma Trials at a Glance

32 actively recruiting trials for advanced melanoma are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in Pittsburgh, Jacksonville, and Houston. Lead sponsors running advanced melanoma studies include Mayo Clinic, M.D. Anderson Cancer Center, and Immunocore Ltd.

Browse advanced melanoma trials by phase

Treatments under study

About Advanced Melanoma Clinical Trials

Looking for clinical trials for Advanced Melanoma? There are currently 26 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 32 trials

Recruiting
Phase 1

AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Advanced MelanomaAdvanced Melanoma and Normal or Impaired
Yale University50 enrolled1 locationNCT07027488
Recruiting
Phase 4

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Lung Non-Small Cell Carcinoma+18 more
OHSU Knight Cancer Institute160 enrolled1 locationNCT07405086
Recruiting
Phase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting
Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Hepatocellular CarcinomaLocally Advanced MelanomaMetastatic Hepatocellular Carcinoma+7 more
National Cancer Institute (NCI)30 enrolled1 locationNCT06066138
Recruiting
Phase 1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8+35 more
M.D. Anderson Cancer Center54 enrolled1 locationNCT05039801
Recruiting
Phase 1Phase 2

A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma

Advanced Melanoma
Nanjing Leads Biolabs Co.,Ltd200 enrolled15 locationsNCT07099430
Recruiting
Phase 3

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Advanced Melanoma
Replimune, Inc.400 enrolled81 locationsNCT06264180
Recruiting
Phase 2

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Advanced Melanoma
Memorial Sloan Kettering Cancer Center88 enrolled12 locationsNCT06594991
Recruiting
Phase 1

NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

SarcomaAdvanced MelanomaMelanoma Metastatic
Centre Hospitalier Universitaire Vaudois9 enrolled2 locationsNCT06889766
Recruiting
Phase 2

A Phase II Trial of LM103 in Advanced Melanoma

Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.92 enrolled13 locationsNCT07310784
Recruiting
Phase 2Phase 3

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Advanced Melanoma
Eikon Therapeutics740 enrolled107 locationsNCT06697301
Recruiting
Phase 1

Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy

Advanced Melanoma
West China Hospital6 enrolled2 locationsNCT07562841
Recruiting
Phase 4

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Metastatic MelanomaAdvanced Melanoma
NYU Langone Health90 enrolled1 locationNCT07504796
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

MelanomaAdvanced MelanomaMelanoma Stage IV+1 more
H. Lee Moffitt Cancer Center and Research Institute90 enrolled1 locationNCT06295159
Recruiting
Not Applicable

High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

Advanced MelanomaSkin CancerMelanoma (Skin)
Fred Hutchinson Cancer Center40 enrolled2 locationsNCT06298734
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 3

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Advanced Melanoma
Immunocore Ltd680 enrolled211 locationsNCT06112314
Recruiting
Phase 3

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Advanced Melanoma
Immunocore Ltd540 enrolled82 locationsNCT05549297
Recruiting
Phase 1Phase 2

A Clinical Study of T3011 in Subjects With Advanced Melanoma

Advanced Melanoma
Shanghai Pharmaceuticals Holding Co., Ltd42 enrolled7 locationsNCT06214156